Core Viewpoint - The U.S. Department of Labor has proposed a regulation aimed at increasing transparency for Pharmacy Benefit Managers (PBMs), which could significantly impact the healthcare industry by revealing hidden fees and compensation structures [1][3]. Group 1: Proposed Regulation - The proposed rule mandates PBMs to disclose their compensation to self-insured group health plans, affecting around 90 million Americans [1]. - The regulation is designed to close loopholes where PBMs allegedly funnel money through subsidiaries to hide fees from drug manufacturers [3]. Group 2: Industry Impact - The timing of the DOL's rule coincides with increased scrutiny over PBMs, particularly regarding their handling of rebates and the use of "shell companies" to obscure fees [2][3]. - Major health insurers like CVS, UnitedHealth, and Cigna could face earnings pressure due to the combined effects of the DOL rule and a flat rate increase in Medicare Advantage payments, which has already led to a significant market value loss [4][6]. Group 3: Financial Mechanisms - Key financial mechanisms involved include spread pricing, rebates, and clawbacks, which are central to the operations of PBMs [7]. - The DOL's regulation aims to ensure that all compensation related to these mechanisms is disclosed, potentially allowing employers to negotiate better deals [8].